The Cogent team is excited about the scientific content at #EHA2024 in Madrid and we’re thrilled to participate in discussions with the hematology community. Come by our booth to learn more!
Cogent Biosciences’ Post
More Relevant Posts
-
Discover the latest developments in myeloma research from the Annual American Society of Hematology meeting. Clinical trial investigators share their abstract presentations from ASH delving deep into the key research takeaways. Watch Now: https://lnkd.in/gaawhHcq #ASH23
To view or add a comment, sign in
-
What are your thoughts about having two classification systems for hematological malignancy? That was one of the interactive audience polls at our Friday Scientific Workshop on translational diagnostics at #ASH23 this year with Irina Murakhovskaya, Bruno Fattizzo and Prof. Dr. med. Dr. phil. Torsten Haferlach. The results as seen on my screen from the podium are below.. the sentiment is relatively clear.. #NGS #hemepath #precisiondiagnostics #summedupwithanemoji #TranslationalMolecularDiagnostics American Society of Hematology
To view or add a comment, sign in
-
HemaTopics are HemaSphere publications focusing on hot hematology topics, including recent research developments, updates on diagnosis and treatment, policy and guidelines news, plus more. This week we focus on the latest HemaTopic by Scientific Editor Roger Schutgens, which discusses the working mechanism, the therapeutic potential and the downsides of imlifidase in a broad range of alloimmune hematological conditions. Read more here 👉https://bit.ly/3SAohy1
To view or add a comment, sign in
-
Dynamic Service Leader||Data Science Enthuist||Ready to make positive impact in healthcare||Medical Content Creator
🔬Amzing Notes About Hematology Review♥️ ✔️Do Share It. 🤔What You Will Learn: 📌Literally Everything About Hematology(From Blood Collection to the Each indices Significance) #knowledgesharing #Laboratoryprofessional #BiomedicalEngineers
To view or add a comment, sign in
-
Mark your calendars for a live webinar hosted by Fortis Institute of Blood Disorder on Innovations in Hematology. Join us on May 17th, 2024, from 7 PM to 8 PM and gain invaluable knowledge from leading specialists Dr. Jayastu Senapati and Dr. Nikhil M Kumar. Discover new technologies and innovative practices that are shaping the future of hematology. #AtFortisWeCare #FortisHealthcare #Webinar
To view or add a comment, sign in
-
HemaTopics are HemaSphere publications focusing on hot hematology topics, including recent research developments, updates on diagnosis and treatment, policy and guidelines news, plus more. This week we focus on the latest HemaTopic by our Scientific Editor David G. Kent where he explores the critical role of endogenous small molecules like ceramide in shaping cellular responses during developmental hematopoiesis. Read more here 👉 https://bit.ly/42vhtp4
To view or add a comment, sign in
-
Today, we are proud to lauch a new product at Hematology TA in Japan. Thank you to all investigators, patients, and colleagues who made this significant achievement possible in Japan. Now is our time; let’s “Go Beyond, for Patients, as One Dream Team!” Vasilisa Sazonov, PhD, Santiago Correa, Kay Moeller-Heske, PhD, Jonathan Van Garsse, Timothy Stiefel, Daisuke Yamashita, Thomas Holbro, KEIICHIRO SETSUNE, Hanae Ishioka, Masashi Umeda
To view or add a comment, sign in
-
Patient Advocate (background in blood cancer MDS), special interest in clinical trials, recent experience of burnout.
To the pharma industry who ask for a guarantee of impact, or measure of impact of proper Patient Engagement: Let's turn it around... Show us that what you are doing works, that all your trials recruit well, and on time. Basically that your 80% failure rate is really great, and an acceptable by product in this industry... And that asking advocates for help to recruit to an impossible trial is also normal... Or ask them for extra QOL data which you 'forgot' to collect... Is this all really successful pharma business? Do some people really know what they are doing? Or is it time to listen for some real help? So no... I don't think we need to prove anything. There is enough proof that global methods don't work most of the time.
During #EHA2024 I had the honor and priviledge to present on the importance of patient involvement in the design of clinical studies. Involvement goes beyong engagement and is relevant and efficient. It has potential to enhance the quality and efficiency of clinical trials. Thanks to the Scientific Working Group on Quality of Life for the opportunity Sam Salek Esther Natalie Oliva Edward Laane European Hematology Association (EHA)
To view or add a comment, sign in
-
HemaTopics are HemaSphere publications focusing on hot hematology topics including recent research developments, updates on diagnosis and treatment, policy and guidelines news, and more. This week we focus on the latest HemaTopic by Scientific Editor Charles de Bock which discusses a recent study from the Ross Levine Lab, which provides a strong rationale for the ongoing development of more potent JAK2 inhibitors. https://bit.ly/43KMqWP
To view or add a comment, sign in
-
How often do you see thrombocytopenic results in your lab? Do you routinely check platelets, white blood cells, or red blood cells in smears during reexaminations triggered by thrombocytopenia? Precise reexamination protocols, efficient execution, and deep hematology expertise are keys to effective thrombocytopenia testing. Here's what lab colleagues have observed in cases of low platelet counts. https://lnkd.in/gHurd_z7 #Hemabook #thrombocytopeniatesting #Mindrayhematology
To view or add a comment, sign in
11,567 followers